Alzheimer’s stop medicine
A new study reveals this Secondary effects from Lecaneemab ControlledAccording to researchers at Washington University (Washo) in the United States. The results of this study are published retroactively in The nerve group.
It must be remembered that the approval of the Food and Drug Administration (FDA) in 2023 from LECANMAB (a new treatment for Alzheimer’s disease First medicine of this type Capable of affecting the disease.
Doubt of possible side effects
However, during clinical trials Side effects arose (Inflammation and cerebral bleeding), which were born doubts between some patients and doctors about treatment.
For this reason, the University of Researchers launched in Washington in San Lewis Study the harmful effects associated with treatment with LECANMAB In their clinical patients, they discovered that the important harmful effects were rare and controlled. The work focused on 234 patients with moderate or very moderate Alzheimer’s disease who received Likanimab batches at the Washo Medical Memory Diagnostic Center, a clinic specialized in treating patients with dementia.
Watching with the results of the clinical trials that carefully controlled, the researchers discovered this Only 1 % of patients have suffered from serious side effects That requires hospitalization. Patients in the initial stage of Alzheimer’s disease with very slight symptoms provided the lowest risk of complications, according to researchers, which helps to inform patients and clinical professionals during talks about the risk of treatment.
The only treatment that affects progress
“This new category of drugs for Alzheimer’s disease early It affects the development of the disease.Points Dr. Barbara Joy Sneider, Professor of Neurology and her main partners for study.
However, fear about the possible side effects of the property can The delay caused treatment. Our study shows that the Washu Medical Clinic Clinic has the infrastructure and expertise needed to manage and serve patients who take Lecaneemab safely, including few who may suffer from serious side effects, which open the way for more clinics to manage the drug safely for patients. “
Lecaneemab is the treatment of antibodies Removes the amyloid board proteinsExtension of an independent life in 10 months, according to a recent study led by researchers from Washo Medicine. Since the amyloid accumulation is the first step of the disease, doctors recommend the medicine for people in the initial stage of Alzheimer’s disease, with slight or very simple symptoms. The researchers discovered that only 1.8 % of patients with very slight alzheimer’s symptoms have developed negative symptoms due to treatment, compared to 27 % of patients with mild Alzheimer’s disease.
Anomalous cases that indicate inflammation and bleeding
“It is possible that you will get the most moderate Alzheimer’s patients The largest benefit and the lowest dangerous “The frequency and evasion can delay the treatment, which in turn increases the risk of side effects. We hope that the results will help rethink conversations between doctors and patients about the risk of the drug,” says Snyder, who brought out the clinical trials of LECANEMAB.
Doubts about Lecaneemab caused by a side effect known as Image distortions related to the amilid (Aria). These anomalies, which usually affect a very small area of the brain, appear in brain explorations and indicate inflammation or bleeding. In clinical trials with Lecaneemab, 12.6 % of ARIA participants and most cases were without symptoms and a solution without interference. A small percentage (about 2.8 % of treated participants) witnessed symptoms such as headache, confusion, nausea and dizziness. Estimates indicate that accidental deaths have been associated with LECANMAB at 0.2 % of patients treated.
Memory Diagnosis Center The treatment of patients with Lecaneemab began in 2023After receiving the total approval of the Food and Drug Administration. Patients receive drugs through injection every two weeks in leakage centers. As part of the care of each patient, Washo Medical Doctors regularly get advanced brain monitoring images, allowing to detect bleeding and inflammation with great sensitivity. Lecaneemab is suspended in patients with symptoms of Arian or Aria without symptoms, and the few patients with severe ARIAD receive the treatment of steroid in the hospital.
The frequency coincides with that which was observed in experiments
When analyzing the results of their patients, the authors note that the size of the side effects CoincideMost of the ARIA cases in the clinic were without symptoms and were only discovered through high allergic brain explorations used to monitor brain changes. Of the 11 patients who have suffered from Aryan symptoms, the effects were resolved to a large extent within a few months and no patient died.
Most patients receive Lecanemab Hold the medicine “Dr. Susan Shendler, a professor participating in neuroscience and participated in the main study. “This report can help patients and health professionals better understand the risk of treatment, and who are minors in patients with very slight symptoms of Alzheimer’s disease.”
Reference
PacZynski M, Hofmann A, Posey Z, Gregorsen M, Rudman M, Ellengton D, Aldinger M, Musiek Es, Holtzman DM, Bateman RJ, Long JM, Ghoshal N, Carr DB, Download A, Namazie-Kummeer S, Jana N, Xiong Lecaneemab treatment in the specialized memory clinic: feasibility and safety. Jama Neurology (2025). Dioo: 10.1001/Jamaneurol.2025.1232
We are already on WhatsApp! If you want to get all the current news and the most important news today, Click here and join our channel. It is a free, comfortable and safe system.
